28 Aug Thomas VanCott, Ph.D.
“When Scheer Partners proposed converting a 72,000 SF preclinical toxicology facility into a new state of the art research & development, vaccine manufacturing and corporate headquarters, I was skeptical that this could be accomplished to the standards we had envisaged for a world-class, state of the art R&D facility.
Given the fact that we had been in our current location for 40+ years, it seemed impossible to marshal the resources necessary to accomplish such a complex undertaking.
In addition to overseeing the commercial lease transaction, Scheer’s team managed the entire construction process as Owner’s Representative. Overseeing the architects, general contractor and accounting procedures was extremely complicated due to the validation process and compacted time schedule.
When we had our grand opening and our Senior Executives flew in from Paris, France they were incredibly impressed and proud of our new facility – thanks to Scheer Partners and their outstanding team!”